There’s been simply no previous prospective study evaluating dual antiplatelet therapy (DAPT) duration shorter than 6?a few months after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation. (CI) 3.6?%] that was less than the pre-defined functionality objective of 6.6?% (check or Wilcoxon rank amount check predicated on their distributions for constant factors. Cumulative incidence was estimated from the Kaplan-Meier method and variations were assessed with the log-rank test. To evaluate the events beyond 3?weeks we also conducted the landmark analyses at 3?months. Those individuals who had the individual endpoint events before 3?weeks AZD5438 were excluded in the landmark analyses. Due to the presence of variations in baseline characteristics between the 2 studies we also used Cox proportional risk models to estimate the risk of the STOPDAPT relative to the RESET for the primary endpoint. In the multivariable analysis we chose 10 clinically relevant factors indicated in Table?1 as the risk adjusting variables. The continuous variables were dichotomized by clinically meaningful reference values or median values. The study (STOPDAPT or SPP1 RESET) and the 10 risk adjusting variables were simultaneously included in the Cox proportional hazard model. The effect of the STOPDAPT compared to the RESET was expressed as hazard ratios (HR) and their 95?% confidence intervals (CI). In the pre-specified sub-group analysis we also conducted the formal interaction test between the study and subgroup factors. Statistical analyses were conducted by a physician (Natsuaki M) and by a statistician (Morimoto T) with the use of JMP 10.0 and SAS 9.4 (SAS Institute Inc Cary NC USA) software. We used one-sided values <0.025 as statistically significant level in the evaluation of performance goal and two-sided values <0.05 as statistically significant for other comparisons. Results Baseline Characteristics: Enrolled versus Non-enrolled Patients in the STOPDAPT Baseline characteristics were significantly different in several aspects between the enrolled and non-enrolled patients (Table?1). Chronic kidney disease hemodialysis heart failure and acute myocardial infarction (AMI) presentation were more prevalent in the non-enrolled group while higher body mass index (BMI) and hypertension were more often found in the enrolled group. Patients with treatment of left main coronary artery were less often enrolled in the study. Regarding the complexity of coronary artery disease the number of AZD5438 treated lesions was greater and multi-vessel treatment was more often performed in the non-enrolled group than in the enrolled group (Table?1). Baseline characteristics: STOPDAPT versus RESET Baseline characteristics were also significantly different in several aspects between the STOPDAPT and RESET (Table?2). Patients in the STOPDAPT were significantly older than those in the RESET. Female gender hypertension dyslipidemia atrial fibrillation AZD5438 anemia and AMI presentation were more often found in the STOPDAPT than in the RESET while diabetes hemodialysis family history of coronary artery disease prior MI heart failure prior PCI and multi-vessel disease were more prevalent in the RESET than in the STOPDAPT. Patients with treatment of left main coronary artery and chronic total occlusion were less often enrolled in the STOPDAPT than in the RESET. Total stent length per AZD5438 patient was significantly longer in the STOPDAPT while multi-vessel treatment was more often performed in the RESET. Regarding the medications at hospital discharge β-blockers and anticoagulants were more often prescribed in the STOPDAPT than in the RESET (Table?2). Table?2 Baseline Characteristics: STOPDAPT versus RESET Angiographic characteristics: STOPDAPT versus RESET In angiographic characteristics thrombus and bifurcation lesions were more often found in the STOPDAPT while in-stent restenosis was more prevalent in the RESET. Lesion length was significantly longer and research vessel size was much larger in the STOPDAPT than in the RESET significantly. There were little but significant variations in in-segment minimum amount lumen size in-segment percent size stenosis and in-segment severe gain between your 2 organizations. SYNTAX score had not AZD5438 been significantly different between your 2 organizations (Desk?3). Desk?3 Baseline angiographic features: STOPDAPT versus RESET Discontinuation of Thienopyridine In the STOPDAPT thienopyridine was discontinued within.